Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells or Circulating DNA in Adult Patients With Metastatic Cancer

Gustave Roussy, Cancer Campus, Grand Paris2,240 enrolled

Overview

Monitoring of circulating endothelial cells (CEC and mature cells called progenitors called CEP) or circulating tumor cells (CTC) in adult patients with metastatic cancer, possibly treated with targeted therapy.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

2,240

Conditions

Metastatic Cancer

Interventions

Blood samplesPROCEDURE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with metastatic solid tumor * Age\> 18 years * Signed consent Exclusion Criteria: * Patients with diseases associated with vascular lesions known. * Patients protected by law, in accordance with Articles L1121-5 to L1121-8 of the Code of Public Health. * Mental pathology that can interfere with the proper conduct of the study. * Refusal of consent.

Locations (1)

Gustave Roussy Cancer Campus Grand Paris

Villejuif, Val de Marne, France

RECRUITING

Outcomes

Primary Outcomes

Measurement and characterization of CEC and CEP and circulaing DNA rate using flow cytometry

Measurement and characterization of initial CEC and CEP circulaing DNA and their evolution under treatment

Time frame: up to 2 years

Central Contacts

Jean Charles Soria, MD-PhD

CONTACT

0142114291 soria@gustaveroussy.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.